Concepedia

Anke Schulz

AS

7

Publications

282

Citations

7

H-Index

2013

Active since

Affiliations

Bayer (Germany)(Current)

University of Colorado Denver

University of Colorado Cancer Center

Bayer (United States)

Antwerp University Hospital

Anke Schulz is an author at Bayer (Germany) specializing in medicine, pathology, and molecular oncology.

Top concepts

Publications per year

2013–2022

7

Publications

7

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

Marion Rudolph, Tobias Anzeneder, Anke Schulz et al. · BMC Cancer · 2016 · 81 citations · Full text

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Jean‐Luc Van Laethem, Hanno Riess, Jacek Jassem et al. · Targeted Oncology · 2016 · 60 citations

, , +10

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial

Paulus Kirchhof, Michael D. Ezekowitz, Yanish Purmah et al. · TH Open · 2020 · 53 citations · Full text

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Alessandro D. Santin, Ignace Vergote, Antonio González-Martı́n et al. · International Journal of Gynecological Cancer · 2022 · 36 citations · Full text

Cytokeratin-19 as a biomarker in urine and in serum for the diagnosis of endometriosis – a prospective study

Lorenz Kuessel, Agnes Jaeger-Lansky, Petra Pateisky et al. · Gynecological Endocrinology · 2013 · 20 citations

, , +17

Rows per page

1–5 of 7